✦ LIBER ✦

Multiple myeloma and cancer: Is there a D-lightful connection?

✍ Scribed by Michael F. Holick

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 57 KB
Volume: 84
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.21450

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Is there an optimal comorbidity index fo

Is there an optimal comorbidity index for prostate cancer?

✍ Shabbir M. H. Alibhai; Marc Leach; George A. Tomlinson; Murray D. Krahn; Neil E. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB

## Abstract ## BACKGROUND. Comorbidity is an important consideration in oncology practice, particularly among older patients. Although a variety of comorbidity indices have been employed in research studies, it is unclear whether any one index is preferred. ## METHODS. An age‐stratified random s

A case-control study of multiple myeloma

A case-control study of multiple myeloma nested in the american cancer society prospective study

✍ P. Boffetta; S. D. Stellman; L. Garfinkel 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 738 KB

Among the subjects enrolled in the American Cancer Society Cancer Prevention Study II, a large nation-wide prospective study, 282 died from multiple myeloma (MM) during the first 4 years of follow-up. These were divided into incident cases who were initially free from disease and prevalent cases who

Extramedullary (EMP) relapse in unusual

Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?

✍ E. Katodritou; V. Gastari; E. Verrou; C. Hadjiaggelidou; M. Varthaliti; S. Georg 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 186 KB

Extramedullary relapse constitutes an uncommon manifestation of multiple myeloma (MM), characterized by highly malignant histology, special biological features, resistance to treatment and poor outcome. Its incidence has been increased during the last years, probably due to the introduction of novel

Complete remission sustained 3 years fro

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

✍ Bart Barlogie; Elias Anaissie; Jeffrey Haessler; Fritz van Rhee; Mauricio Pineda 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 387 KB

Is there a role for microsurgery in the

Is there a role for microsurgery in the prevention of arm lymphedema secondary to breast cancer treatment?

✍ C. Campisi; D. Davini; C. Bellini; G. Taddei; G. Villa; E. Fulcheri; A. Zilli; E 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

## Abstract The secondary lymphedema of the upper limb (post‐mastectomy lymphedema) has an incidence, in patients who underwent axillary lymphadenectomy for breast cancer, between 5 to 25%, up to 40% after radiotherapic treatment. We studied 50 patients treated for breast cancer. The patients were

Weekly treatment with bortezomib for pat

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma : A phase 2 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; David R. Spigel; John Barton; Cindy Farley; Marshall Schreed 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 2 views

## Abstract ## BACKGROUND. The purpose of the current study was to evaluate the efficacy and toxicity of weekly bortezomib in the treatment of patients with recurrent/refractory multiple myeloma. ## METHODS. A total of 40 patients with multiple myeloma who had received either 1 or 2 previous tre